News

Mr Fox is a chairman and non-executive director at Biota Holdings, non-executive director and deputy chairman at Elders Limited; and non-executive director at Air New Zealand, MS Research

Progenics said that the monoclonal antibodies were identified as part of its ongoing drug discovery efforts in infectious diseases. The data were presented at the 110th General Meeting

Eyeing a huge opportunity in contract manufacturing space, the new division, DRS Labs, will begin operations with an initial capital of INR100m. After receiving all statutory clearances, DRS

Proteoderm said that the new product, Proteoderm PS (physician strength) is designed to provide a specific dosage of the active ingredient Matrix NC-138, to the patient depending on

Lialda is used to treat ulcerative colitis, proctitis, and proctosigmoiditis. It is also used to prevent the symptoms of ulcerative colitis from recurring. Shire said that Lialda is

Using its proprietary ProMIS computational platform discovery technology, Amorfix has identified several disease specific epitopes (DSEs) on misfolded Fas receptor. Aragen is expected to use those DSEs to

Amira said that this is the second patent granted of a large estate filed by it that describe small molecule inhibitors of the DP2 (CRTH2) receptor. Amira has

As per the expanded agreement, Restanza’s in-vitro activity against Neisseria gonorrhoeae and other key STI’s is expected to be assessed, to advance Restanza into clinical development in government-sponsored

GeoVax Labs claimed that although the company’s vaccines are currently being studied for HIV prevention, this is the first study using the same products for treatment of persons